Published in Biotech Business Week, August 11th, 2008
-- Non-GAAP Total Revenues Increased 63 Percent to $566.6 Million; GAAP Total Revenues $571.5 Million
-- REVLIMID(R) Net Product Sales Increased 80 Percent to $325.8 Million
-- Global THALOMID(R)/Thalidomide Net Product Sales Reached $131.6 Million
-- VIDAZA(R) Net Product Sales Achieved $59.7 Million
-- Non-GAAP Operating Income Increased 60 Percent to $207.0 Million; GAAP Operating Income $140.0 Million
-- Non-GAAP Net Income Increased to $172.7 Million; GAAP Net Income $119.9 Million
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.